“…Brain age has a range of potential applications for the clinical assessment of individual patients at various stages of health and disease, including the support of diagnosis, prognosis, and treatment decisions ( Figure 3 ). Brain age studies are being conducted in a wide range of clinical populations including neurological conditions such as Alzheimer's disease (AD) and mild cognitive impairment (MCI) [ 1 , 14 , 15 , 25 , 37 , [56] , [57] , [58] , [59] ], traumatic brain injury [ 60 , 61 ], epilepsy [ 18 , 19 , 62 ], multiple sclerosis [ 37 , 54 , 63 ], and stroke [ 64 , 65 ], as well as psychiatric disorders such as schizophrenia [ 10 , 12 , 69 , 20 , 26 , 37 , 38 , 45 , [66] , [67] , [68] ], including clinical high-risk for psychosis (CHR) and first-episode psychosis (FEP), bipolar disorder [ 37 , 38 , 66 , 67 , 70 ], major depressive disorder (MDD) [ 6 , 20 , 32 , 37 , 71 , 72 ], borderline personality disorder [20] , autism spectrum disorder [ 8 , 37 , 73 ], and attention deficit hyperactivity disorder [37] . The results of the clinical studies are summarised in Tables 1 and 2 .…”